Pay in 4 interest-free payments of $6.07 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
As part of the settlement, ESI agreed to, among other things: Stop preferring high-WAC drugs over low-WAC alternatives on its standard formulary Provide standard offering that ensures members OOP costs are based on drugs net price, not list price Provide plans and beneficiaries with access to TrumpRx as part of its standard offering Provide a standard offering that allows plans to transition off rebate guarantees and spread pricing Delink manufacturers compensation to ESI from list prices as part of its standard offering Increase transparency with drug-level reporting Standard offering to include retail pharmacies will receive cost-plus reimbursement Move Ascent Health Services GPO from Switzerland to US Promote standard offerings to plans & retail pharmacies Increased Oversight, Access, and Enforcement by the FTC, including compliance with multiyear monitoring requirements, submission 0f compliance reports as required by the FTC, cooperation with litigation in certain contexts, and granting FTC access to facilities, personnel, and records as FTC deems necessary These requirements align with federal PBM reform activities and will transform ESIs offering
Gabler M, Picker N, Geier S et al (2021) Real-world clinical outcomes and costs in type 2 diabetes mellitus patients after initiation of insulin therapy: a German claims data analysis
Sajad Zalzala, MD, SkinnyRx Medical Director Missed GLP-1 doses arent always the result of a lapse in memory
Subcutaneous injections dominate this segment with a 64% market share, offering robust efficacy and established preference among healthcare providers
US$ 21.64
US$ 21.52
US$ 25.73
US$ 28.96
US$ 24.45
US$ 24.51
US$ 21.99
US$ 22.12
US$ 23.84
